You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Accession NumberDB00873  (APRD01078)
TypeSmall Molecule
DescriptionLoteprednol (as Loteprednol Etabonate) is a topical corticoid antiinflammatory. It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides. As a nasal spray, is used for the treatment and management of seasonal allergic rhinitis.
External IDs CDDD 5604 / HGP 1 / P 5604
Product Ingredients
IngredientUNIICASInChI KeyDetails
Loteprednol etabonateYEH1EZ96K6 82034-46-6DMKSVUSAATWOCU-HROMYWEYSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlrexSuspension / drops2 mg/mLOphthalmicBauch & Lomb Incorporated1998-03-09Not applicableUs
AlrexSuspension0.2 %OphthalmicBausch & Lomb Inc2009-06-24Not applicableCanada
AlrexSuspension / drops2 mg/mLOphthalmicStat Rx USA1998-03-09Not applicableUs
AlrexSuspension / drops2 mg/mLOphthalmicPhysicians Total Care, Inc.2002-10-17Not applicableUs
LotemaxSuspension / drops5 mg/mLOphthalmicPhysicians Total Care, Inc.2002-10-17Not applicableUs
LotemaxSuspension0.5 %OphthalmicBausch & Lomb Inc2009-06-24Not applicableCanada
LotemaxOintment5 mg/gOphthalmicBauch & Lomb Incorporated2011-04-15Not applicableUs
LotemaxSuspension / drops5 mg/mLOphthalmicBauch & Lomb Incorporated1998-03-09Not applicableUs
LotemaxGel5 mg/gOphthalmicBauch & Lomb Incorporated2012-10-12Not applicableUs
Lotemax GelGel0.5 %OphthalmicBausch & Lomb Inc2015-06-25Not applicableCanada
Lotemax OintmentOintment0.5 %OphthalmicBausch & Lomb Inc2014-10-29Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
LoteflamCipla Pharmaceuticals Limited
Brand mixtures
ZyletBauch & Lomb Incorporated
CAS number129260-79-3
WeightAverage: 394.889
Monoisotopic: 394.154701681
Chemical FormulaC21H27ClO5
chloromethyl (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[²,⁷.0¹¹,¹⁵]heptadeca-3,6-diene-14-carboxylate
[H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
IndicationAs an ophthalmic it is used for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides. As a nasal spray, used for the treatment and management of seasonal allergic rhinitis.
Structured Indications
PharmacodynamicsLoteprednol etabonate (LE) is a "soft" steroid belonging to a unique class of glucocorticoids. LE possesses a metabolically labile 17 beta-chloromethyl ester function which was designed in order to be hydrolyzed to an inactive carboxylic acid moiety. This inactive metabolite is more hydrophilic and is thus readily eliminated from the body. Loteprednol etabonate has good ocular permeation properties and good skin permeation properties similar to "hard" steroids. It is used as a topical agent for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis and iritis.
Mechanism of actionLoteprednol etabonate (LE) is a "soft" steroid belonging to a unique class of glucocorticoids. Loteprednol etabonate is structurally similar to other glucocorticoids. However, the number 20 position ketone group is absent. It is highly lipid soluble which enhances its penetration into cells. Loteprednol etabonate is synthesized through structural modifications of prednisolone- related compounds so that it will undergo a predictable transformation to an inactive metabolite. It first binds to the type II glucocorticoid receptor. Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
HumanP04150 details
Related Articles
AbsorptionVery limited systemic absorption, but good absorption at the point of delivery.
Volume of distributionNot Available
Protein bindingNot Available

The drugs 17 beta-chloromethyl ester function is hydrolyzed to an inactive carboxylic acid moiety.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityAdverse effects include abnormal vision / blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions Not Available
Food InteractionsNot Available
Synthesis ReferenceNot Available
General References
  1. Pavesio CE, Decory HH: Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008 Apr;92(4):455-9. doi: 10.1136/bjo.2007.132621. Epub 2008 Feb 1. [PubMed:18245274 ]
External Links
ATC CodesS01BA14
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (1.1 MB)
MSDSDownload (57.6 KB)
Clinical Trials
Clinical Trials
1CompletedNot AvailablePharmacokinetics1
1CompletedSupportive CareOcular Pain1
2CompletedPreventionConjunctivitis, Seasonal Allergic1
2CompletedTreatmentDry Eye Syndromes / Keratoconjunctivitis Sicca1
2CompletedTreatmentDry Eyes1
2CompletedTreatmentKeratoconjunctivitis Sicca1
2CompletedTreatmentBacterial blepharitis1
3Active Not RecruitingTreatmentPost Surgical Ocular Inflammation and Pain1
3CompletedTreatmentCataracts / Inflammatory processes / Pain2
3CompletedTreatmentConjunctivitis, Seasonal Allergic1
3CompletedTreatmentBacterial blepharitis / Conjunctivitis / Keratitis1
3CompletedTreatmentOcular Infections, Irritations and Inflammations1
3CompletedTreatmentInflammatory processes / Pain2
3CompletedTreatmentOcular inflammatory conditions2
3RecruitingTreatmentDry Eye Syndromes / Keratoconjunctivitis Sicca2
4Active Not RecruitingTreatmentConjunctivitis, Giant Papillary / Conjunctivitis, Seasonal Allergic / Inflammatory processes1
4Active Not RecruitingTreatmentMeibomian Gland Dysfunction (MGD) / Posterior Blepharitis1
4CompletedPreventionCorneal Edema / Fuchs' Dystrophy1
4CompletedTreatmentCataract Extraction1
4CompletedTreatmentChalazion / Hordeolum1
4CompletedTreatmentConjunctivitis, Seasonal Allergic2
4CompletedTreatmentDry Eye Disease (DED)1
4CompletedTreatmentDry Eye Disease (DED) / Keratoconjunctivitis Sicca1
4CompletedTreatmentEpithelial Defect After Phototherapeutic Keratectomy1
4CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
4CompletedTreatmentInflammatory processes1
4Not Yet RecruitingTreatmentMust be PRK Candidate1
4Unknown StatusPreventionCataract operation / Pseudophakia1
4Unknown StatusTreatmentContact Lenses Dryness1
4WithdrawnTreatmentDry Eye Disease (DED)1
Not AvailableCompletedNot AvailableOcular Hypertension1
Not AvailableCompletedPreventionDry Eyes1
Not AvailableCompletedTreatmentDiabetic Macular Edema (DME) / Retinal Vein Occlusion (RVO)1
Not AvailableUnknown StatusNot AvailableInflammatory processes / Pseudophakia1
Not AvailableUnknown StatusTreatmentDry Eye Syndrome (DES)1
Not AvailableUnknown StatusTreatmentDry Eyes1
Not AvailableUnknown StatusTreatmentPost-operative Healing Following Blepharoplasty and Ptosis Repair1
  • Bausch and lomb inc
  • Pharmos corp
Dosage forms
SuspensionOphthalmic0.2 %
Suspension / dropsOphthalmic2 mg/mL
GelOphthalmic5 mg/g
OintmentOphthalmic5 mg/g
SuspensionOphthalmic0.5 %
Suspension / dropsOphthalmic5 mg/mL
GelOphthalmic0.5 %
OintmentOphthalmic0.5 %
Suspension / dropsOphthalmic
PricesNot Available
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2174550 No2002-10-012014-10-21Canada
US4996335 No1995-03-092012-03-09Us
US5540930 No1993-10-252013-10-25Us
US5800807 No1997-01-292017-01-29Us
Experimental Properties
melting point220-224 °CNot Available
water solubility5 mg/mLNot Available
logP3.4Not Available
Predicted Properties
Water Solubility0.0336 mg/mLALOGPS
pKa (Strongest Acidic)12.01ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area83.83 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity102.65 m3·mol-1ChemAxon
Polarizability41.29 Å3ChemAxon
Number of Rings4ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Human Intestinal Absorption+0.9884
Blood Brain Barrier+0.9294
Caco-2 permeable+0.5426
P-glycoprotein substrateSubstrate0.7489
P-glycoprotein inhibitor INon-inhibitor0.6379
P-glycoprotein inhibitor IINon-inhibitor0.6419
Renal organic cation transporterNon-inhibitor0.7633
CYP450 2C9 substrateNon-substrate0.862
CYP450 2D6 substrateNon-substrate0.914
CYP450 3A4 substrateSubstrate0.794
CYP450 1A2 substrateNon-inhibitor0.8987
CYP450 2C9 inhibitorNon-inhibitor0.8866
CYP450 2D6 inhibitorNon-inhibitor0.872
CYP450 2C19 inhibitorNon-inhibitor0.9233
CYP450 3A4 inhibitorNon-inhibitor0.5687
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8468
Ames testNon AMES toxic0.8574
BiodegradationNot ready biodegradable0.9614
Rat acute toxicity2.2305 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9647
hERG inhibition (predictor II)Non-inhibitor0.5773
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Mass Spec (NIST)Not Available
SpectraNot Available
DescriptionThis compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassAndrostane steroids
Direct ParentAndrogens and derivatives
Alternative Parents
  • Androgen-skeleton
  • 3-oxo-delta-1,4-steroid
  • 3-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Cyclic ketone
  • Secondary alcohol
  • Carboxylic acid ester
  • Ketone
  • Carboxylic acid derivative
  • Monocarboxylic acid or derivatives
  • Organochloride
  • Organooxygen compound
  • Organic oxygen compound
  • Carbonyl group
  • Hydrocarbon derivative
  • Alkyl halide
  • Alkyl chloride
  • Alcohol
  • Organohalogen compound
  • Organic oxide
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors


Pharmacological action
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
Uniprot ID:
Molecular Weight:
85658.57 Da
  1. Druzgala P, Hochhaus G, Bodor N: Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol. 1991 Feb;38(2):149-54. [PubMed:2004037 ]
  2. Bodor N, Buchwald P: Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des. 2006;12(25):3241-60. [PubMed:17020532 ]
  3. Szelenyi I, Hochhaus G, Heer S, Kusters S, Marx D, Poppe H, Engel J: Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20. [PubMed:12861354 ]
  4. Samudre SS, Lattanzio FA Jr, Williams PB, Sheppard JD Jr: Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther. 2004 Dec;20(6):533-47. [PubMed:15684812 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 27, 2017 04:04